Thomas Feldthus
Chief Executive Officer chez SANA AB
Fortune : 205 641 $ au 31/03/2024
Profil
Thomas Feldthus is the founder of Symphogen A, Aniona ApS, Saniona AB, and Scandion Oncology A.
Symphogen A was founded in 2000, Aniona ApS in 2012, Saniona AB in 2011, and Scandion Oncology A in 2017.
He held the title of Chief Financial Officer at Symphogen A from 2000 to 2012.
He is a Director at Aniona ApS and Saniona AB, and a Director at Scandion Oncology A.
Mr. Feldthus previously holds multiple positions, including Chief Executive Officer & Director at Fertilizer Invest ApS, Chairman at Rehaler ApS, Chief Financial Officer & Director at Saniona A, Director at ResoTher Pharma AS, and Director at Synklino.
A.
He previously held positions as Director-Business Development at Cheminova A, Manager-Corporate Development at Novo Nordisk A, Investment Associate at Novo Holdings AS (Denmark), Investment Manager at Novo Ventures 1 A, and Chief Financial Officer at Wntresearch AB from 2012 to 2015.
Mr. Feldthus received a graduate degree from the University of London and the Technical University of Denmark, and an MBA degree from the London Business School.
Mr. Feldthus is also the founder of Leukotech A, Ataxion, Inc., Initiator Pharma A.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SANIONA AB
1,03% | 29/08/2023 | 1 140 488 ( 1,03% ) | 205 641 $ | 31/03/2024 |
Postes actifs de Thomas Feldthus
| Sociétés | Poste | Début |
|---|---|---|
| SANA AB | Chief Executive Officer | 30/04/2022 |
Saniona A/S
 Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | Director of Finance/CFO | - |
Synklino A/S
 Synklino A/S BiotechnologyHealth Technology Synklino A/S develops a CMV-specific immunotoxin that aims to eliminate cytomegalovirus infections. | Director/Board Member | - |
Rehaler ApS
 Rehaler ApS Medical SpecialtiesHealth Technology Rehaler ApS develops medical devices for the treatment of migraine. | Chairman | - |
ResoTher Pharma AS
 ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | Director/Board Member | - |
| Fertilizer Invest ApS | Chief Executive Officer | - |
Aniona ApS
 Aniona ApS Medical/Nursing ServicesHealth Services Aniona ApS is a private company based in Ballerup, Denmark. Jørgen Drejer has been the CEOs since incorporation. The Danish company was founded by Thomas Feldthus, Anker Gunvald Lundemose, Claus Tycho Bræstrup, Jørgen Drejer. | Founder | 01/09/2012 |
Anciens postes connus de Thomas Feldthus
| Sociétés | Poste | Fin |
|---|---|---|
| WNTRESEARCH AB | Director of Finance/CFO | 01/06/2015 |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Founder | 02/04/2012 |
| ░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░ | - |
| ░░░░ ░░░░░░░░ ░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Thomas Feldthus
| University of London | Graduate Degree |
| Technical University of Denmark | Graduate Degree |
| London Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| WNTRESEARCH AB | Health Technology |
| SANA AB | Health Technology |
| INITIATOR PHARMA A/S | Health Technology |
| SCANDION ONCOLOGY A/S | Health Technology |
| Entreprise privées | 12 |
|---|---|
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) MiscellaneousMiscellaneous Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Miscellaneous |
Cheminova A/S
 Cheminova A/S Chemicals: AgriculturalProcess Industries Cheminova A/S manufactures pesticides and other agrochemical products. It offers herbicides, insecticides, fungicides, seed dressings, regulants, grain protectants, and animal health products. The company was founded by Gunnar Andreasen in 1938 and is headquartered in Harboøre, Denma rk. | Process Industries |
Leukotech A/S
 Leukotech A/S Pharmaceuticals: MajorHealth Technology Leukotech A/S develops and manufactures pharmaceutical products. It develops agents for prevention and treatment of life-threatening infections and severe inflammatory disorders. The company is headquartered in Copenhagen, Denmark. | Health Technology |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Finance |
Aniona ApS
Aniona ApS Medical/Nursing ServicesHealth Services Aniona ApS is a private company based in Ballerup, Denmark. Jørgen Drejer has been the CEOs since incorporation. The Danish company was founded by Thomas Feldthus, Anker Gunvald Lundemose, Claus Tycho Bræstrup, Jørgen Drejer. | Health Services |
| Fertilizer Invest ApS | |
Ataxion, Inc.
 Ataxion, Inc. BiotechnologyHealth Technology Ataxion, Inc. develops novel therapies for rare, debilitating, and underserved neurologic diseases. It focuses on orphan genetic disorders termed hereditary ataxias. It was founded by Josh Resnick and David Grayzel in April 2013 and is headquartered in Cambridge, MA. | Health Technology |
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | Commercial Services |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | Health Technology |
Rehaler ApS
Rehaler ApS Medical SpecialtiesHealth Technology Rehaler ApS develops medical devices for the treatment of migraine. | Health Technology |
Synklino A/S
Synklino A/S BiotechnologyHealth Technology Synklino A/S develops a CMV-specific immunotoxin that aims to eliminate cytomegalovirus infections. | Health Technology |
